Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study
Jamiyah Hassan, Teck-Hock Toh, Selva Kumar Sivapunniam, Ruziaton Hasim, Nor Faizah Ghazali, Sofiah Sulaiman, Mia Tuang Koh, Stephanie Meyer, Myew-Ling Toh, Celine Zocchetti, Claire Vigne, Cesar Mascareñas, Jamiyah Hassan, Teck-Hock Toh, Selva Kumar Sivapunniam, Ruziaton Hasim, Nor Faizah Ghazali, Sofiah Sulaiman, Mia Tuang Koh, Stephanie Meyer, Myew-Ling Toh, Celine Zocchetti, Claire Vigne, Cesar Mascareñas
Abstract
Background: Incorporating dengue vaccination within existing vaccination programs could help improve dengue vaccine coverage. We assessed the immunogenicity and safety of a quadrivalent human papillomavirus (HPV) vaccine administered concomitantly or sequentially with a tetravalent dengue vaccine (CYD-TDV) in healthy children 9-13 years of age in Malaysia.
Methods: In this phase IIIb, open-label, multicenter study (NCT02993757), participants were randomized 1:1 to receive 3 CYD-TDV doses 6 months apart and 2 doses of quadrivalent HPV vaccine concomitantly with, or 1 month before (sequentially), the first 2 CYD-TDV doses. Only baseline dengue-seropositive participants received the 3 doses. Antibody levels were measured at baseline and 28 days after each injection using an enzyme-linked immunosorbent assay for HPV-6, -9, -16 and -18, and the 50% plaque reduction neutralization test for the 4 dengue serotypes; immunogenicity results are presented for baseline dengue-seropositive participants. Safety was assessed throughout the study for all participants.
Results: At baseline, 197 of 528 (37.3%) randomized participants were dengue-seropositive [n = 109 (concomitant group) and n = 88 (sequential group)]. After the last HPV vaccine dose, antibody titers for HPV among baseline dengue-seropositive participants were similar between treatment groups, with between-group titer ratios close to 1 for HPV-6 and 0.8 for HPV-11, -16, and -18. After CYD-TDV dose 3, dengue antibody titers were similar between treatment groups for all serotypes [between-group ratios ranged from 0.783 (serotype 2) to 1.07 (serotype 4)]. No safety concerns were identified.
Conclusions: The immunogenicity and safety profiles of CYD-TDV and quadrivalent HPV vaccines were unaffected when administered concomitantly or sequentially in dengue-seropositive children.
Conflict of interest statement
J.H., N.F.G., R.H. and S.S. received a grant from Sanofi Pasteur to conduct this study. J.H. received personal fees from Merck Sharp & Dohme, Johnson & Johnson, DKSH Malaysia, Nestle Malaysia, Ferring Pharmaceuticals, Sanofi Malaysia, Zuellig Pharma Malaysia, Abex Medical Systems, Abbott Malaysia and Bayer Malaysia; S.S. received personal fees from Dutch Lady during the 36 months before submitting this manuscript, outside the submitted work. C.M., C.V., C.Z., M.-L.T. and S.M. are employees of Sanofi Pasteur. The other authors have no conflicts of interest to disclose.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Figures
References
- World Health Organization. Dengue vaccine: WHO position paper, September 2018 - Recommendations. Vaccine. 2019;37:4848–4849.
- World Health Organization. Dengue and severe dengue. WHO factsheet. 2020. Available at: . Accessed June 29, 2020.
- Tambo E, Chen JH, Zhou XN, et al. . Outwitting dengue threat and epidemics resurgence in Asia-Pacific countries: strengthening integrated dengue surveillance, monitoring and response systems. Infect Dis Poverty. 2016;5:56.
- Halstead S, Wilder-Smith A. Severe dengue in travellers: pathogenesis, risk and clinical management. J Travel Med. 2019;26:taz062.
- Redondo-Bravo L, Ruiz-Huerta C, Gomez-Barroso D, et al. . Imported dengue in Spain: a nationwide analysis with predictive time series analyses. J Travel Med. 2019;26:taz072.
- Sanofi Pasteur. Dengvaxia, powder and solvent for suspension for injection in pre-filled syringe dengue tetravalent vaccine (live, attenuated). Summary of Product Characteristics. Available at: .
- Sanofi Pasteur Inc. DENGVAXIA® (Dengue Tetravalent Vaccine, Live). Full Prescribing Information. 2019.Swiftwater, USA: Sanofi Pasteur Inc
- Capeding MR, Tran NH, Hadinegoro SR, et al. .; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–1365.
- Villar L, Dayan GH, Arredondo-García JL, et al. .; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113–123.
- Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. .; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195–1206.
- Sabchareon A, Wallace D, Sirivichayakul C, et al. . Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–1567.
- Sridhar S, Luedtke A, Langevin E, et al. . Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–340.
- World Health Organization. Global strategy for dengue prevention and control, 2012–2020. Available at: . Accessed April 2020.
- World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Releve epidemiologique hebdomadaire. 2017;92:241–268.
- Paavonen J, Naud P, Salmerón J, et al. .; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–314.
- Markowitz LE, Dunne EF, Saraiya M, et al. . Human papillomavirus vaccination recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 2014;63:1–30.
- World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017-recommendations. Vaccine. 2017;35:5753, 5755.
- Merck Sharp & Dohme Corp. GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Suspension for intramuscular injection. Prescribing Information. 2006. Available at: . Accessed April 2020.
- Timiryasova TM, Bonaparte MI, Luo P, et al. . Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg. 2013;88:962–970.
- Moodie Z, Juraska M, Huang Y, et al. . Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J Infect Dis. 2018;217:742–753.
Source: PubMed